Droxidopa (Northera)
Small molecule
Evidence outlook
Approved: Neurogenic Orthostatic Hypotension
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
track record: Partial signal
Also in development:Parkinson's Disease · Phase 3 · investigational in the US
Also approved (1)
- Droxidopa (Dainippon Sumitomo Pharma): frozen gait and dizziness on standing associated with Parkinson's disease, and orthostatic hypotension
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
NCT01176240 NCT01176240 · Orthostatic Hypotension, Parkinson's Disease The study randomized participants to droxidopa or matched placebo and maintained quadruple blinding, with 225 enrolled overall, but the two prespecified primary comparisons were discordant. The 306B primary symptom endpoint favored droxidopa statistically, whereas the 306A questionnaire endpoint did not, so the findings provide useful but limited evidence rather than a consistent demonstration of benefit. Registry: NCT01176240 | 3 | 306A Efficacy: Change in Orthostatic Hypotension Questionnaire Score (OHQ) (Baseline, Week 8); 306B Efficacy: Change in Dizziness/Lightheadedness/Feeling Faint/Feeling Like You Might Black Out (OHSA Item 1) (Baseline, Week1) 2012-10 | 306A Efficacy: Change in Orthostatic Hypotension Questionnaire Score (OHQ) (Baseline, Week 8): Droxidopa -2.2 units on a scale (Standard Deviation 2.44) vs Placebo -2.1 units on a scale (Standard Deviation 2.49) | Partial signal | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 3 (7)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 2/3 (2)
What this study did
What this study did
Phase 2 (12)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 1/2 (5)
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 1 (5)
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 4 (6)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Early phase / not applicable (2)
What this study did
What this study did
Competitive landscape
This drug's own stage for Neurogenic Orthostatic Hypotension: Approved. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Droxidopa (Northera): this drug | Approved | Small molecule | norepinephrine precursor | Partial signal | NCT01176240: 306A Efficacy: Change in Orthostatic Hypotension Questionnaire Score (OHQ) (Baseline, Week 8): Droxidopa -2.2 units on a scale (Standard Deviation 2.44) vs Placebo -2.1 units on a scale (Standard Deviation 2.49) | |
| Ampreloxetine (TD-9855) | Discontinued | Small molecule | norepinephrine transporter | Partial signal | NCT05696717: CYPRESS (NCT05696717), primary endpoint change in OHSA composite score at Week 8: result was not statistically significant. missed NCT03750552: Change From Baseline in Orthostatic Hypotension Symptom Assessment (OHSA) Question #1 Score at Week 4 (Baseline and Week 4): Ampreloxetine -1.69 score on a scale (Standard Error 0.29) | Placebo -1.45 score on a scale (Standard Error 0.293) missed |
Upcoming events
(3 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow Droxidopa (Northera) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.